BAJAJ BROKING

Notification
No new Notification messages
Senores Pharmaceuticals IPO is Open!
Apply for the Senores Pharmaceuticals IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.

Dr. Lal PathLabs Q2 Results FY24-25 Highlights: Revenue at ₹660 Cr up 9.8%, PAT at ₹131 Cr up 18.1%

Listen to our Podcast: Grow your wealth and keep it secure.

0:00 / 0:00

Synopsis:

Dr. Lal PathLabs reported a 9.8% revenue growth to ₹660 crore in Q2 FY24-25, while PAT increased by 18.1% to ₹130 crore. Growth was driven by core diagnostic services and wellness testing, reflecting the company’s market leadership and operational excellence.

Dr. Lal PathLabs Limited reported a consolidated revenue of ₹660 crore, showing a 9.8% increase year-on-year for Q2 FY24-25. The company also recorded a Profit After Tax (PAT) of ₹131 crore, reflecting an 18.1% YoY growth. The diagnostics giant continues to perform strongly despite evolving market conditions, maintaining its leadership in diagnostic services across India.

Key Highlights/Quick Insights

  • Revenue: ₹660 crore (9.8% growth YoY)
  • PAT (Profit After Tax): ₹131 crore (18.1% growth YoY)
  • EBITDA Margin: 30.7%, reflecting operational efficiency
  • Second Interim Dividend: ₹6 per share declared for FY25

DR. LAL PATH LABS LTD.

Trade

2927.1-19.09 (-0.64 %)

Updated - 24 December 2024
2959.80day high
DAY HIGH
2926.75day low
DAY LOW
283770
VOLUME (BSE)

Quarterly - Dr. Lal PathLabs Q2 Results FY24-25

Dr. Lal PathLabs posted consolidated revenue of ₹660 crore in Q2 FY24-25, a 9.8% year-on-year increase compared to ₹601 crore in Q2 FY23-24. The company's Profit After Tax (PAT) for the quarter stood at ₹131 crore, marking an 18.1% growth compared to ₹111 crore in the same period last year. The robust performance is driven by continued demand for diagnostic services and the company’s expansion into new test categories.

Sector Expectations for Dr. Lal PathLabs Q2 Results FY24-25

Dr. Lal PathLabs’ Q2 results align with sector expectations, reflecting steady growth in the diagnostics market, driven by increasing demand for preventive healthcare services and routine testing. The sector continues to expand as awareness about health monitoring increases. The company's focus on wellness testing, along with a broad diagnostic portfolio, positions it strongly for future growth.

Management Commentary

Dr. Lal PathLabs considered & took note that Dr. Om Prakash Manchanda will be stepping down as Managing Director of the Company on account of completion of tenure on March 31, 2025 (closing of business hours). However, after completion of tenure as Managing Director, he will remain as an advisor to the Company.

Dr. Lal PathLabs Q2 Results FY’24-25 Highlights:

Particulars

Q2 FY24-25 (Reported)

YoY Change

Revenue

₹660.2 Cr

9.80%

EBITDA Margin

30.70%

13.90%

PAT

₹130.8 Cr

18.10%

Second Interim Dividend per Share

₹ 6

 

Conclusion

Dr. Lal PathLabs’ Q2 FY24-25 results highlight its strong financial performance, with revenue growing by 9.8% and PAT increasing by 18.1%. The company’s ongoing focus on expanding its diagnostic portfolio and preventive health offerings continues to fuel growth, positioning it as a leader in the diagnostics industry.

Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.

This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.

For All Disclaimers Click Here: https://bit.ly/3Tcsfuc

Share this article: 

Read More Blogs

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

8 Lacs+ Users

icon-with-text

4.4+ App Rating

icon-with-text

4 Languages

icon-with-text

₹4700+ Cr MTF Book

icon-with-text